Equities

Modalis Therapeutics Corp

4883:TYO

Modalis Therapeutics Corp

Actions
  • Price (JPY)101.00
  • Today's Change-7.00 / -6.48%
  • Shares traded8.35m
  • 1 Year change-34.42%
  • Beta0.6773
Data delayed at least 20 minutes, as of Sep 20 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of JPY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments1,8832,9334,936
Total Receivables, Net------
Total Inventory6.3540--
Prepaid expenses------
Other current assets, total6788131
Total current assets1,9563,0615,067
Property, plant & equipment, net----224
Goodwill, net------
Intangibles, net----705
Long term investments------
Note receivable - long term------
Other long term assets706973
Total assets2,0263,1306,069
LIABILITIES
Accounts payable------
Accrued expenses921826
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total106124155
Total current liabilities198142181
Total long term debt41300
Total debt41300
Deferred income tax----5.05
Minority interest------
Other liabilities, total3547334
Total liabilities646189520
SHAREHOLDERS EQUITY
Common stock1,2182,0952,744
Additional paid-in capital2,5393,4174,066
Retained earnings (accumulated deficit)(2384)(2586)(1266)
Treasury stock - common(0.1)(0.1)(0.1)
Unrealized gain (loss)------
Other equity, total7.32165.16
Total equity1,3802,9415,549
Total liabilities & shareholders' equity2,0263,1306,069
Total common shares outstanding332929
Treasury shares - common primary issue0.000.000.00
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.